Phase 1 and 2 Study of PX-866 and Cetuximab
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01252628 |
|
Recruitment Status :
Completed
First Posted : December 3, 2010
Last Update Posted : May 16, 2018
|
Sponsor:
Cascadian Therapeutics Inc.
Information provided by (Responsible Party):
Seagen Inc. ( Cascadian Therapeutics Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | November 2013 |
| Actual Study Completion Date : | January 2014 |
| Certification/Extension First Submitted : | April 30, 2015 |